Premium
Intensive Treatment of Pseudomonas Chest Infection in Cystic Fibrosis: a Comparison of Tobramycin and Ticarcillin, and Netilmicin and Ticarcillin
Author(s) -
CONWAY S. P.,
MILLER M. G.,
RAMSDEN C.,
LITTLEWOOD J. M.
Publication year - 1985
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1985.tb10929.x
Subject(s) - netilmicin , medicine , ticarcillin , tobramycin , cystic fibrosis , sputum , aminoglycoside , gentamicin , anesthesia , antibiotics , pseudomonas aeruginosa , ceftazidime , microbiology and biotechnology , pathology , tuberculosis , biology , genetics , bacteria
. Seventeen cystic fibrosis patients aged 3.1 years to 19.8 years had 30 courses of intensive treatment for relapse of their pseudomonas chest infection. The combination of netilmicin and ticarcillin was compared with tobramycin and ticarcillin in an open study. A significant subjective and objective improvement occurred in all patients. Pseudomonas was cleared temporarily from the sputum in 11 out of the 30 courses of treatment (37 %). There was no significant difference between the netilmicin and tobramycin groups, nor evidence of sustained renal or ototoxicity. Intensive therapy of pseudomonas chest infection in cystic fibrosis patients is described in detail.